Recent breakthroughs reveal the use of advanced artificial intelligence models in protein engineering and drug discovery. Researchers at Integra Therapeutics, in partnership with academic institutions, have designed synthetic proteins capable of genome editing with higher efficiency than natural counterparts. Simultaneously, major pharmaceutical companies including AbbVie, Johnson & Johnson, and Takeda have pooled proprietary structural data to train large language models for AI-enhanced drug design, accelerating discovery processes while safeguarding data privacy. These developments highlight AI’s growing influence in biotechnological innovation with potential broad applications.